Pharmaceutical Tariffs Discussion

John Flavin, CEO of Portal Innovations, addressed the Trump administration’s proposed pharmaceutical tariffs during his appearance on CNBC’s ‘Squawk on the Street’. He highlighted potential challenges for biotech startups and clinical trials, emphasizing concerns over the future of U.S. drug innovation.

Impact on Biotech Startups

Flavin warned that the tariffs could hinder the growth of biotech startups, which often rely on affordable drug components. He noted that increased costs could stifle innovation and slow down the development of new therapies.

Clinical Trials Challenges

The proposed tariffs may complicate the logistics of clinical trials, as rising costs could limit access to essential materials. Flavin expressed concern that this could lead to delays in bringing new drugs to market.